ACC Prevails Upon Boston Scientific To Present More Data At Late Breaker

In an unusual reversal of a statement it made two days ago, Boston Scientific announced this afternoon that it would present all three co-primary endpoints of the PREVAIL clinical trial this Saturday at the American College of Cardiology scientific sessions in San Francisco. The PREVAIL trial, which was designed to confirm the safety and efficacy of the Watchman left atrial appendage closure device, is one of the most highly-anticipated late-breaking clinical trials at the ACC this year.

As reported here yesterday, earlier this week Boston Scientific said that the principal investigator of the trial, David Holmes, would only “present the acute procedural safety results.” This was a highly unusual development, since late-breaking clinical trial sessions are intended to provide the medical community with its first look at the main results of important clinical trials. By all accounts, the ACC was unhappy with the Boston Scientific announcement and initiated discussions with the company shortly after the announcement.

Click here to read the full story on Forbes.


Leave a Reply

%d bloggers like this: